Cystatin C and baseline renal function among HIV-infected persons in the SUN study

AIDS Research and Human Retroviruses

Volumn 28, Issue 2, 2012, Pages 148-155

  Overton, Edgar Turner ^a   Patel, Pragna ^b   Mondy, Kristin ^c   Bush, Tim ^b   Conley, Lois ^b   Rhame, Frank ^d,e   Kojic, Erna Milunka ^f   Hammer, John ^g   Henry, Keith ^e,h   Brooks, John T ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d ABBOTT NORTHWESTERN HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MIRIAM HOSPITAL   (United States)

^g Denver Infectious Disease Consultants   (United States)

^h HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CYSTATIN C; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NONHUMAN; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; HYPERTENSION; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RITONAVIR;

EID: 84858055332     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0018     Document Type: Article

References (51)

1. Palella FJ, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34. (Pubitemid 44306484)
2. Lampe FC, Smith CJ, Madge S, et al.: Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007;167:692-700. (Pubitemid 46598462)
3. Lucas GM, Eustace JA, Sozio S, et al.: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998;352:783-784.
4. Ross MJ and Klotman PE: Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002;13:2997-3004. (Pubitemid 35386920)
5. Jones R, Stebbing J, Nelson M, et al.: Renal dysfunction with tenofovir disproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-1495. (Pubitemid 39602339)
6. Schwartz EJ, Szczech LA, Ross MJ, et al.: Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412-2420. (Pubitemid 41725059)
7. Mocroft A, Kirk O, Gatell J, et al.: Chronic renal failure among HIV-1-infected patients. AIDS 2007;21:1119-1127. (Pubitemid 46763282)
8. Gupta SK, Eustace JA, Winston JA, et al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:15590-15595.
9. Röling J, Schmid H, Fischereder M, et al.: HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy Clin Infect Dis 2006;42:1488-1495.
10. Verhelst D, Mone M, Meynard JL, et al.: Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis 2002;40:1331-1333. (Pubitemid 35403147)
11. Peyrière H, Reynes J, Rouanet I, et al.: Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr Hum Retrovirol 2004;35:269-273. (Pubitemid 38280652)
12. Gallant JE, Parish MA, Keruly JC, and Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase treatment. Clin Infect Dis 2005;40:1194-1198. (Pubitemid 40490248)
13. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19:4555-4562.
14. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, Brooks JT, and the HIV Outpatient Study Investigators: Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic IL) 2007;6:178-187.
15. Baekken M, Os I, Sandvik L, and Oektedalen O: Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy. J Hypertens 2008;26:2126-2133.
16. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al.: HIV infection and the risk of diabetes mellitus. AIDS 2009;23:1227-1234.
17. Clinical practice guidelines of the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation. Available at www.kidney.org/ professionals/kdoqi/guidelines.cfm. Accessed 1 May 2010.
18. Shemesh O, Golbetz H, Kriss JP, and Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-838. (Pubitemid 16156326)
19. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez- Brú C, and Grubb A: Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005;38:1-8. (Pubitemid 39647648)
20. Grubb A, Simonsen O, Sturfelt G, Truedsson L, and Thysell H: Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985;218:499-503. (Pubitemid 16147646)
21. Simonsen O, Grubb A, and Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985;45:97-101. (Pubitemid 15106618)
22. Stevens LA, Coresh J, Schmid CH, et al.: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406. (Pubitemid 351273480)
23. Shlipak MG, Katz R, Kestenbaum B, et al.: Rate of kidney function decline in older adults: A comparison using creatinine and cystatin C. Am J Nephrol 2009;30:171-178.
24. Odden MC, Chertow GM, Fried LF, et al.: Cystatin C and measures of physical function in elderly adults: The Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol 2006;164:1180-1189. (Pubitemid 44950386)
25. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, and Shlipak MG: Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: The FRAM study. Arch Intern Med 2007;167:2213-2219. (Pubitemid 350106741)
26. Jones CY, Jones CA, Wilson IB, et al.: Cystatin C and creatinine in an HIV cohort: The nutrition for healthy living study. Am J Kidney Dis 2008;51:914-924. (Pubitemid 351697573)
27. Mocroft A, Wyatt C, Szczech L, et al.: Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009;23:71-82.
28. Vellozzi C, Brooks JT, Bush TJ, et al.: The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). Am J Epidemiol 2009;169:642-652.
29. Finney H, Newman DJ, and Price CP: Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000;37:49-59. (Pubitemid 30064225)
30. Knight EL, Verhave JC, Spiegelman D, et al.: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421. (Pubitemid 38406982)
31. Shlipak MG, Sarnak MJ, Katz R, et al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060. (Pubitemid 40664306)
32. Shlipak MG, Katz R, Sarnak MJ, et al.: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246. (Pubitemid 46768607)
33. de Silva TI, Post FA, Griffin MD, and Dockrell DH: HIV-1 infection and the kidney: An evolving challenge in HIV medicine. Mayo Clin Proc 2007;82:1103-1116. (Pubitemid 47357143)
34. Fine DM, Perazella MA, Lucas GM, and Atta MG: Renal disease in patients with HIV infection: Epidemiology, pathogenesis and management. Drugs 2008;68:963-980. (Pubitemid 351652924)
35. Madero M and Sarnak MJ: Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens 2009;18:258-263.
36. Shlipak MG: Cystatin C research priorities targeted to clinical decision making. Am J Kidney Dis 2008;51:358-361.
37. Knight EL, Verhave JC, Spiegelman D, et al.: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421. (Pubitemid 38406982)
38. Menon V, Shlipak M, Wang X, et al.: Cystatin C as a risk factor for outcomes in CKD. Ann Intern Med 2007;147:19-27. (Pubitemid 351664630)
39. Dharnidharka VR, Kwon C, and Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002;40:221-226. (Pubitemid 34827638)
40. 2. Am J Kidney Dis 2010;56:486-495.
41. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, and Krediet RT: Performance of the Cockcroft- Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5:1003-1009.
42. Rodriguez-Nóvoa S, Alvarez E, Labarga P, and Soriano V: Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9:545-559.
43. Jenh AM, Thio CL, and Pham PA: Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 2009;29:1212-1227.
44. Okwundu CI and Okoromah CA: Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2009;1:CD007189.
45. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
46. Kuller LH, Tracy R, Belloso W, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
47. Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, Schauseil S, and Schmutz G: Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008;13:1091-1095.
48. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, and Shlipak MG: Kidney function and markers of inflammation in elderly persons without chronic kidney disease: The health, aging, and body composition study. Kidney Int 2007;71:239-244. (Pubitemid 46160924)
49. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, and Larson TS: Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006;69:399-405. (Pubitemid 43323094)
50. Xu Y, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea H, Dickins RA, and Villadangos JA: IL-10 Controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol 2011;186:3666-3673.
51. Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, Yamane S, Pei Z, Kojima S, Hamano Y, Mashiba S, Kurata M, Miyoshi K, and Higaki J: Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol 2010;14:584-588.